Teva introduces generic Intuniv

JERUSALEM — The latest addition to Teva’s roster of medication is its generic version of Intuniv (guanfacine) extended release tablets in 1-, 2-, 3- and 4-mg dosage strengths.

 

Intuniv, which according to March IMS data made $804 million in total sales, is meant to treat attention deficit hyperactivity disorder. The launch of guanfacine brings Teva’s total number of ADHD drugs to eight, and it is the first non-stimulant ADHD drug in its portfolio.

 

 “We recognize the need to make affordable generic treatment options available to patients with ADHD,” Brendan O’Grady, Teva’s President and CEO, North America Generic Medicines, said.